pSivida Corp (PVA)

Shares / Stock Code

PVA

Stock Exchange / Sharemarket

ax

pSivida (PVA) is an international bio-nanotech company specialising in the development of drug-delivery products in the healthcare industry, with its core focus on ophthalmology and oncology. pSivida listed on the Australian Stock Exchange (ASX) on 12 June, 2008. It is also listed on NASDAQ (PSDV) and Frankfurt (PSI) stock exchanges. pSividia is included in the NASDAQ Health Care Index (Nasdaq: IXHC) and the Merrill Lynch Nanotechnology Index. pSivida sources its revenue from marketed products. The Company holds a portfolio of diversified late-stage products including a next generation product Medidur™ which is licensed for ophthalmic applications to Pfizer Inc. Medidur™ is completely funded by its licensing partner Alimera Sciences, for treating Diabetic Macular Edema. PVA has developed only two FDA approved sustained release back of the eye treatments focusing chronic eye disease, Vitrasert® and Retisert®. Bausch & Lomb which is a global ophthalmology company is engaged in the manufacture and sale of both of these products. pSivida also holds the licence for the development and commercialisation of a new biomaterial, nanostructured porous silicon (BioSilicon™), for a range of potential applications in healthcare initially in drug delivery. Its leading BioSilicon™ product is BrachySil™. BrachySil™ is a brachytherapy treatment currently in Phase II clinical trials, targeting inoperable pancreatic cancer. Pfizer is the largest shareholder and strategic partner of PVA, with QinetiQ which is one of the largest European R&D institutions is a top five shareholder in the Company.

pSivida Corp History

pSvida was listed on the Australian Stock Exchange in 2008. Its core patent, which recognises BioSilicon as a biomaterial, received approval in the UK in 2000 and in the US in 2001. pSivida's R&D work in the field of nanomedicine was acknowledged with the prestigious 2004 Frost & Sullivan Excellence in Research Award.